User profiles for Jens Siveke
 | Jens SivekeUniversity of Duisburg-Essen Verified email at uni-due.de Cited by 12771 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global …
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …
[PDF][PDF] EGF receptor is required for KRAS-induced pancreatic tumorigenesis
Initiation of pancreatic ductal adenocarcinoma (PDA) is definitively linked to activating
mutations in the KRAS oncogene. However, PDA mouse models show that mutant Kras …
mutations in the KRAS oncogene. However, PDA mouse models show that mutant Kras …
Pancreatic cancer: basic and clinical aspects
G Schneider, JT Siveke, F Eckel, RM Schmid - Gastroenterology, 2005 - gastrojournal.org
More than 30,000 people develop pancreatic adeno-carcinoma each year in the United States,
and almost all are expected to die from the disease. 1 The 5-year survival rate is 5%, and …
and almost all are expected to die from the disease. 1 The 5-year survival rate is 5%, and …
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and
shows resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors …
shows resistance to any therapeutic strategy used. Here we tested small-molecule inhibitors …
Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers
Rare cancers are difficult to treat; in particular, molecular pathogenesis–oriented medical
therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing …
therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing …
Cutting edge: T helper 1 and T helper 2 cells respond differentially to chemokines
T effector subsets, such as Th1 or Th2 cells, are key players in inflammatory reactions. It is
not known whether chemokines are able to recruit these subsets differentially, as has been …
not known whether chemokines are able to recruit these subsets differentially, as has been …
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma
…, G Klöppel, RM Schmid, JT Siveke - Proceedings of the …, 2010 - National Acad Sciences
Pancreatic cancer is one of the most fatal malignancies lacking effective therapies. Notch
signaling is a key regulator of cell fate specification and pancreatic cancer development; …
signaling is a key regulator of cell fate specification and pancreatic cancer development; …
The latest developments in imaging of fibroblast activation protein
A Altmann, U Haberkorn, J Siveke - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
… Jens Siveke receives research funding from Celgene and BMS; receives personal fees
from AstraZeneca, BMS, Celgene, Immunocore, Novartis, and Roche; and holds ownership in …
from AstraZeneca, BMS, Celgene, Immunocore, Novartis, and Roche; and holds ownership in …
[PDF][PDF] Liver‐specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice
The Notch pathway is an evolutionary conserved, intercellular signaling pathway that plays
an important role in cell fate specification and the embryonic development of many organs, …
an important role in cell fate specification and the embryonic development of many organs, …
[HTML][HTML] NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
A Wang-Gillam, RA Hubner, JT Siveke… - European Journal of …, 2019 - Elsevier
Background Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is
approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously …
approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously …